A012103: OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY (Location: Aberdeen)

Objective

Clinical Trial Details >>

Principal Investigator(s)
Alexandra (Ally) Higgins, MD

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Contact
Breast Research Coordinators at 605-322-1432
or breastresearch@avera.org

Location

  • Avera Cancer Institute — Aberdeen
    310 S Penn St
    Suite 106
    Aberdeen, SD 57401
    Main: 605-622-8700